Editing Management of Localized and Locally Advanced Disease (section)

=== Follow-up after ablation ===
* '''Patients who have undergone ablation should be followed with contrast-enhanced imaging (MRI or CT)''' to assess for residual enhancing disease and post-procedure complications.
** '''Ultrasound should not be used for post-ablation surveillance'''
* '''Schedule'''
** '''2021 AUA'''
*** '''If biopsy confirmed malignancy or was non-diagnostic, pre- and post-contrast cross-sectional abdominal imaging should be done within 6 months after TA.'''
*** '''Subsequent follow-up should be according to the intermediate-risk recommendations (see Table 1 from original guidelines)'''
** '''2018 CUA'''
*** '''Surveillance is similar to low-risk except for abdominal imaging (CT or MRI) at 3, 6, and 12 months, then annually thereafter for up to 5 years.'''
**** '''CXR is recommended annually during follow-up'''
*** If pre-treatment biopsy demonstrated oncocytoma and imaging post-ablation shows treatment success, routine imaging beyond one year is not recommended